Recalcitrant neovascular macular degeneration after anti-VEGF therapy: an ongoing challenge.
This editorial describes the challenge of managing eyes that demonstrate signs of persistent exudation after anti-VEGF treatment and illuminates the significance of a new report of using high-dose ranibizumab in treating recalcitrant neovascular age-related macular degeneration.